https://www.technologynetworks.com/drug-discovery/news/parion-sciences-announces-initiation-of-phase-i-clinical-trial-to-evaluate-safety-and-tolerability-of-gs9411-204783
The initiation of the trial triggers a $5 million milestone payment from Gilead Sciences, according to an exclusive licensing and co-development agreement.
clinical trialparionsciencesannouncesinitiation